摘要
目的探讨尼可地尔联合左卡尼汀治疗缺血性心肌病心力衰竭老年患者的临床疗效和安全性。方法将纳入的缺血性心肌病心力衰竭老年患者随机分为2组:对照组和试验组各42例,对照组用尼可地尔每次5 mg,3次/次;在对照组基础上,试验组给予左卡尼汀注射液2 g静脉滴注。治疗2个月后,评价患者的临床疗效,记录治疗前后的左室射血分数(LVEF),测定患者的C反应蛋白(CRP)和氨基末端脑钠肽前体(NT-proBNP)水平,记录药物不良反应(ADR)状况。结果治疗后,试验组和对照组的总有效率分别为95.24%(40例/42例)和80.95%(34例/42例),组间比较差异有统计学意义(P<0.05)。试验组和对照组的LVEF分别为(55.16±7.43)%和(49.20±7.27)%;这2组的CRP分别为(8.67±2.67)和(13.52±3.10)mg·L-1;这2组的NT-proBNP分别为(345.72±101.05)和(513.26±124.01)ng·L-1。上述指标:组间比较差异均有统计学意义(均P<0.05)。治疗期间无ADR发生。结论尼可地尔联合左卡尼汀对缺血性心肌病心力衰竭老年患者的疗效确切,能改善心功能,降低NT-proBNP和CRP水平,且安全性高。
Objective To investigate the clinical effect and safety of nicorandil combined with levocarnitine in the treatment of elderly patients with ischemic cardiomyopathy and heart failure.Methods Included elderly patients with ischemic cardiomyopathy and heart failure were randomly divided into 2 groups:42 cases in the control group and 42 cases in the treatment group.The control group received nicorandil 5 mg,tid,orally;on the basis of the control group,the treatment group received levocarnitine injection 2 g intravenously.After 2 months of treatment,the clinical efficacy was evaluated.The levels of left ventricular ejection fraction(LVEF),C-reactive protein(CRP),amino terminal brain natriuretic peptide precursor(NT-proBNP)were determined.The adverse drugs reactions(ADR)was recorded.Results After treatment,the total effective rate in the treatment group and the control group were 95.24%(40 cases/42 cases)and 80.95%(34 cases/42 cases),the difference was statistically significant(P<0.05).After treatment,the LVEF in treatment group and the control group were respectively(55.16±7.43)%and(49.20±7.27)%;CRP in the two groups were respectively(8.67±2.67)and(13.52±3.10)mg·L-1;NT-proBNP in the two groups were respectively(345.72±101.05)and(513.26±124.01)ng·L-1.The differences of the factors between the two groups were statistically significant(all P<0.05).No ADR occurred during the treatment.Conclusion The effect of nicorandil combined with levocarnitine on elderly patients with ischemic cardiomyopathy and heart failure is definite,which can improve cardiac function,reduce the levels of NT-proBNP and CRP,and the safety is high.
作者
朱仕现
何汉康
陈剑
刘果果
韦冬梅
石磊
ZHU Shi-xian;HE Han-kang;CHEN Jian;LIU Guo-guo;WEI Dong-mei;SHI Lei(Department of Cardiology,Liuzhou Hospital of Traditional Chinese Medicine,Liuzhou 545000,Guangxi Zhuang Autonomous Region,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2020年第21期3410-3413,共4页
The Chinese Journal of Clinical Pharmacology
基金
广西壮族自治区卫生和计划生育委员会自筹经费科研课题项目(Z20170800)。
关键词
尼可地尔
左卡尼汀
缺血性心肌病心力衰竭
氨基末端脑钠肽前体
心功能
nicorandil
levocarnitine
ischemic cardiomyopathy and heart failure
amino terminal brain natriuretic peptide precursor
cardiac function
